0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > CD47

CD47

Brief Information

Name:Cluster of differentiation 47
Target Synonym:MER6,CD47,Leukocyte surface antigen CD47,CD47 Molecule,Antigenic Surface Determinant Protein OA3,CD47 Antigen (Rh-Related Antigen, Integrin-Associated Signal Transducer),Antigen Identified By Monoclonal Antibody 1D8,Integrin Associated Protein,Rh-Related
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:20
Lastest Research Phase:NDA/BLA

Product ListCompare or Buy

Cat. No. Species Product Description Structure Purity Feature
MBS-K023 Human Human CD47-coupled Magnetic Beads
MBS-K023-elisa_1
CD7-H82A3 Human Biotinylated Human CD47 Protein, Mouse IgG2a Fc,Avitag™ (MALS verified)
CD7-H82A3-structure
CD7-H82A3-sds
CD7-H82A3-elisa_1
CD7-HF2H3 Human FITC-Labeled Human CD47 Protein, His Tag
CD7-HF2H3-structure
CD7-HF2H3-sds
CD7-HF2H3-elisa_1
CD7-H82F8 Human Biotinylated Human CD47 Protein, Fc (L234A, L235A, P329G),Avitag™
CD7-H82F8-structure
CD7-H82F8-sds
CD7-H82F8-elisa_1
CD7-M82E4 Mouse Biotinylated Mouse CD47 Protein, His,Avitag™
CD7-M82E4-structure
CD7-M82E4-sds
CD7-M82E4-elisa_1
CD7-C52H5 Canine Canine CD47 Protein, His Tag
CD7-C52H5-structure
CD7-C52H5-sds
CD7-C52H5-elisa_1
EP-102 Human CD47: SIRP alpha [Biotinylated] Inhibitor Screening ELISA Assay Pair
EP-102-elisa_1
CD7-H522a Human Human CD47 Protein, His Tag, low endotoxin
CD7-H522a-structure
CD7-H522a-sds
CD7-H522a-elisa_1
CD7-H5251 Human Human CD47 Protein, Llama IgG2b Fc Tag, low endotoxin
CD7-H5251-structure
CD7-H5251-sds
CD7-H5251-elisa_1
CD7-M525a Mouse Mouse CD47 Protein, Mouse IgG2a Fc Tag, low endotoxin
CD7-M525a-structure
CD7-M525a-sds
CD7-M525a-elisa_1
CD7-M522b Mouse Mouse CD47 Protein, His Tag
CD7-M522b-structure
CD7-M522b-sds
CD7-M522b-elisa_1
CD7-C52H1 Cynomolgus / Rhesus macaque Cynomolgus / Rhesus macaque CD47 Protein, His Tag
CD7-C52H1-structure
CD7-C52H1-sds
CD7-C52H1-elisa_1
CD7-C52H1-elisa_2
CD7-HA2E9 Human Unconjugated Human CD47 Protein, His,Avitag™
CD7-HA2E9-structure
CD7-HA2E9-sds
CD7-HA2E9-elisa_1
CD7-H82E9 Human Biotinylated Human CD47 Protein, His,Avitag™
CD7-H82E9-structure
CD7-H82E9-sds
CD7-H82E9-elisa_1
CD7-R5257 Rabbit Rabbit CD47 Protein, Fc Tag
CD7-R5257-structure
CD7-R5257-sds
CD7-R5256 Rat Rat CD47 Protein, Fc Tag
CD7-R5256-structure
CD7-R5256-sds
CD7-R5256-elisa_1
CD7-H52A5 Human Human CD47 Protein, Mouse IgG2a Fc Tag, low endotoxin
CD7-H52A5-structure
CD7-H52A5-sds
CD7-H52A5-elisa_1
CD7-C5252 Cynomolgus / Rhesus macaque Cynomolgus / Rhesus macaque CD47 Protein, Fc Tag
CD7-C5252-structure
CD7-C5252-sds
CD7-C5252-elisa_1
CD7-M5251 Mouse Mouse CD47 Protein, Fc Tag
CD7-M5251-structure
CD7-M5251-sds
CD7-H82F6 Human Biotinylated Human CD47 Protein, Fc,Avitag™
CD7-H82F6-structure
CD7-H82F6-sds
CD7-H82F6-elisa_1
CD7-H5227 Human Human CD47 Protein, His Tag
CD7-H5227-structure
CD7-H5227-sds
CD7-H5227-elisa_1
CD7-H5227-elisa_2
CD7-H5256 Human Human CD47 Protein, Fc Tag (MALS verified)
CD7-H5256-structure
CD7-H5256-sds
CD7-H5256-hplc
CD7-H5256-elisa_1

Part of Bioactivity data

CD7-H82E9-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

FACS assay shows that Biotinylated Human CD47, His,Avitag (Cat. No. CD7-H82E9) can bind to ACHN cell expressing human SIRP-a. The concentration of CD47 used is 10 μg/mL (Routinely tested).

CD7-H82E9-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

FACS analysis shows that the binding of Human CD47 to ACHN expressing SIRP-a was inhibited by increasing concentration of neutralizing SIRP-a antibody. The concentration of Human CD47 used is 20 μg/mL. IC50=9.334 μg/mL

CD7-C52H1-SPR
Human_FcRn_Heterodimer_Protein_SPR

Anti-CD47 Mab (Human IgG4) captured on CM5 chip via anti-human IgG Fc antibodies surface, can bind Cynomolgus/Rhesus macaque CD47, His Tag (Cat. No. CD7-C52H1) with an affinity constant of 1.8 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

CD7-H5227-SPR
Human_FcRn_Heterodimer_Protein_SPR

Anti-Human CD47 MAb (Human IgG4) captured on CM5 chip via Anti-Human IgG Fc antibodies surface, can bind Human CD47, His Tag (Cat. No. CD7-H5227) with an affinity constant of 1.66 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

Customer Reviews

Synonym Name

CD47,MER6,IAP,OA3

Background

Leukocyte surface antigen CD47 is also known as Antigenic surface determinant protein OA3, Integrin-associated protein (IAP) and Protein MER6. CD47 contains 1 Ig-like V-type (immunoglobulin-like) domain. CD47 is very broadly distributed on normal adult tissues. CD47 has a role in both cell adhesion by acting as an adhesion receptor for THBS1 on platelets, and in the modulation of integrins and plays an important role in memory formation and synaptic plasticity in the hippocampus by similarity. CD47 is the receptor for SIRPA, binding to which prevents maturation of immature dendritic cells and inhibits cytokine production by mature dendritic cells. CD47 Interaction with SIRPG mediates cell-cell adhesion, enhances superantigen-dependent T-cell-mediated proliferation and costimulates T-cell activation.

Clinical and Translational Updates

Related Molecule

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
SRF-231 SRF-231 Phase 1 Clinical Surface Oncology Hematologic Neoplasms Details
Anti-CD47 monoclonal antibody (Biocad) Phase 1 Clinical Biocad Neoplasms Details
AO-176 AO-176; Ti-104; Ti-108; Ti-176 Phase 2 Clinical Arch Oncology Solid tumours; Neoplasms; Multiple Myeloma Details
IMC-002 IMC-002 Phase 1 Clinical Immuneoncia Therapeutics Solid tumours; Neoplasms; Lymphoma Details
IMM-0306 IMM-0306 Phase 1 Clinical ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd Lymphoma, B-Cell Details
ZL-1201 ZL-1201 Phase 1 Clinical Zai Lab (Shanghai) Co Ltd Hematologic Neoplasms; Solid tumours Details
TG-1801 NI-1701; TG-1801 Phase 1 Clinical Novimmune Lymphoma, B-Cell, Marginal Zone; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
HX-009 HX-009 Phase 2 Clinical Hangzhou Hansi Biomedicine Co Ltd, Wuhan Hanxiong Biotechnology Co Ltd Solid tumours; Liver Neoplasms; Hematologic Neoplasms; Stomach Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Non-Small-Cell Lung; Melanoma Details
SG404 SG-404; SG404 Phase 1 Clinical Hangzhou Sumgen Biotechnology Co Ltd Neoplasms Details
IMM2505 IMM2505 Phase 1 Clinical Shenghe (China) Biopharmaceutical Co Ltd Solid tumours Details
IMM-2902 IMM-2902 Phase 1 Clinical ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd Solid tumours Details
lemzoparlimab TJ-011133; TJC-4 Phase 2 Clinical I-Mab Biopharma Co Ltd Solid tumours; Myelodysplastic Syndromes; Lymphoma; Leukemia, Myeloid, Acute Details
Kintuzumab(GenSci) Phase 1 Clinical Changchun Genescience Pharmaceutical Co Ltd Solid tumours; Hematologic Neoplasms; Lymphoma Details
TTI-622 TTI-622 Phase 1 Clinical Trillium Therapeutics Inc Multiple Myeloma; Leukemia, Myeloid, Acute; Lymphoma Details
IBI-188 IBI-188 Phase 3 Clinical Innovent Biologics(Suzhou) Co Ltd Solid tumours; Adenocarcinoma of Lung; Myeloproliferative Disorders; Neoplasms; Myelodysplastic Syndromes; Osteosarcoma; Leukemia, Myeloid, Acute Details
PF-07257876 Phase 1 Clinical Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Non-Small-Cell Lung Details
AK-117 AK-117 Phase 2 Clinical Zhongshan Akeso Biopharma Co Ltd Solid tumours; Neoplasms; Myelodysplastic Syndromes; Leukemia, Myeloid, Acute; Lymphoma Details
TQB2928 Phase 1 Clinical Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd Hematologic Neoplasms; Solid tumours Details
STI-6643 STI-6643 Phase 1 Clinical Sorrento Therapeutics Inc Solid tumours Details
Monoclonal Antibody (Mab) sB24M Phase 1 Clinical Pyoderma Gangrenosum Details
JMT-601 JMT-601 Phase 1 Clinical Shanghai Jinmante Biological Technology Co Ltd Lymphoma, Non-Hodgkin Details
IMM 01(ImmuneOnco Biopharma) IMM01; IMM 01 Phase 1 Clinical ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd Lymphoma Details
DSP-107 DSP-107; KAHR-107 Phase 2 Clinical Kahr Medical Solid tumours; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Leukemia, Myeloid, Acute; Carcinoma, Non-Small-Cell Lung Details
TTI-621 TTI-621 Phase 2 Clinical University Health Network, The Hospital For Sick Children Leukemia, Promyelocytic, Acute; Solid tumours; Leiomyosarcoma; Hematologic Neoplasms; Papillomavirus Infections; Breast Neoplasms; Sarcoma; Carcinoma, Squamous Cell; Mycosis Fungoides; Melanoma Details
CC-90002 INBRX-103; CC-90002 Phase 1 Clinical Inhibrx Hematologic Neoplasms; Myelodysplastic Syndromes; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin Details
Magrolimab 5-F-9; Hu5F9-G4; ONO-7913 Phase 3 Clinical Stanford University Hematologic Neoplasms; Ovarian Neoplasms; Solid tumours; Leukemia, Myeloid; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Transitional Cell; Myelodysplastic Syndromes; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms; Multiple Myeloma; Colorectal Neoplasms; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin Details
CPO-107 Phase 2 Clinical Conjupro Biotherapeutics Inc Lymphoma, Non-Hodgkin Details
ALX-148 ALX148; ALX-148 Phase 3 Clinical Alexo Therapeutics Head and Neck Neoplasms; Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Myelodysplastic Syndromes; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Adenocarcinoma; Neoplasm Metastasis Details

This web search service is supported by Google Inc.

totop